Skip to main content

Clinical Research from Clinical Investigation Services

Call Today to Qualify

Open Hours

Monday – Friday 8 am to 5pm

Have you been diagnosed with Rheumatoid Arthritis?

Trial Information:

The Xbiotech 2021-PT055 study will assess the safety and effectiveness of Natrunix (human antibody preparation) in combination with Methotrexate (MTX) to determine the ACR 20 response rate. ACR response is the measure of improvement in percentage of RA disease. The disease activity is checked at two different time points, one before the study drug and one after the study drug.

A key purpose of this study to determine if Natrunix could improve some common symptoms of rheumatoid arthritis like loss of joint function, pain, and long-term breakdown of cartilage etc.

This trial is running at three of our affiliate research sites:

  • Orland Park, IL (Dr. Cory Conniff)
  • Schaumburg, IL (Dr. Kamran Chaudhary)
  • Skokie, IL (Dr. Robert Hozman)

For more information on this clinical trial, please call us at 847-691-3856 and ask to speak to our recruiter Maria.

Flyer for the Xbiotech 2021-PT055 study.

Study Protocol: Xbiotech 2021-PT055

General Contact Form
Select the best time(s) to contact you.

Dr. Eva Agaiby

President, Director of Clinical Trials & Regulatory Affairs

View Profile

Allen Banoub, MBA

Director of Marketing & Business Development

View Profile